Clinical Trial Search

Primary: Number of Subjects With Combined Clinical and Microbiologic Response — 70 Participants

Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…

Primary: Number of Participants Who Were Cured — 120; 130 Participants — p=<0.001

Primary: Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success — 62.6; 36.0 percentage of participants

Primary: Clinical Cure — 140; 123; 10; 27 participants

Primary: Number of Participants With Clinical Cure at Day 7 — 13; 12 participants

Primary: Microbiological Response Assessment Profile — 58; 63 Participants

Primary: Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT)…

Primary: Number of Participants With Overall Success — 36; 17 Participants

Primary: Number of Participants With Microbiological Response at the Test of Cure (ToC) Visit — 10; 10; 1; 18 Participants

Primary: Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S…

Primary: Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy — 111; 122 Participants

Primary: Overall Success — 318; 260 Participants

Primary: Number of Participants Experiencing Urinary Tract Infection Within 6 Weeks of Surgery — 13; 13 Participants — p=0.97

Primary: Eligible Subjects That Were Enrolled in the Study — 70 Participants

Primary: Area Under the Plasma Concentration-time Curve (AUC) From Zero (Pre-dose) Over the Dosing Interval (AUC[0-tau]) of Gepotidacin — 20236.2; 29313.8 Hours* nanogram per…

Primary: The Number of Patients Receiving Appropriate Treatment — 44; 29 Participants

Primary: Incidence of Adverse Drug Reactions During 7-day Treatment of uUTI Symptoms With Canephron® N — 0 Adverse Drug Reactions

Primary: Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC) — 80.7 Percentage of participants

Primary: Post-operative Urinary Tract Infection — 19; 20 Participants

Primary: Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test — 276; 276; 103; 124 Participants

Primary: Percentage of Participants Achieving Clinical Symptom Improvement at 24 Hours (±4 Hours) — 54.4 Percentage of participants

Primary: Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the EOI Visit — 363; 382; 51; 7 Participants

Primary: Composite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) Population — 207; 83 Participants — p=0.0088

Primary: Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test — 276; 276; 103; 124 Participants

Primary: The Main Outcome Measure Was the Incidence of Urinary Tract Infection (UTI) Post-urodynamic Study (UDS), Diagnosed Through Urinalysis Indicating Leukocyturia, Positive…

Primary: Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S…

Primary: Favorable Clinical Outcomes (FCl) — 170; 132 Participants

Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as…

Primary: Percentage of Participants With Overall Success — 301; 325 Participants